Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003926 · ClinicalTrials.gov registry record · Phase 1
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
A Phase 1 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00003926 is a Phase 1 study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 13 participants.
The verdict
NCT00003926, a Phase 1 study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of high-dose chemotherapy. PURPOSE: Phase I trial to study the effectiveness of amifostine in protecting from the side effects of peripheral stem cell transplantation in treating patients who have high-risk or relapsed solid tumors.
Interventions
- DRUG melphalan
- DRUG filgrastim
- DRUG thiotepa
- DRUG busulfan
- DRUG amifostine trihydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 1998-11 |
| Est. Completion | 2003-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003926
The ClinicalTrials.gov registry entry for NCT00003926 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which melphalan is the first listed.
NCT00003926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003926 about?
NCT00003926 is a clinical study titled "Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Chemoprotective drugs su...
What is the current status of trial NCT00003926?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 1998-11. Estimated completion is 2003-08.
What interventions are being tested in trial NCT00003926?
The interventions under investigation include: melphalan (DRUG), filgrastim (DRUG), thiotepa (DRUG), busulfan (DRUG), amifostine trihydrate (DRUG).
Who is sponsoring clinical trial NCT00003926?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.